Literature DB >> 26508312

Updated EAU Guidelines for Clear Cell Renal Cancer Patients Who Fail VEGF Targeted Therapy.

Thomas Powles1, Michael Staehler2, Börje Ljungberg3, Karim Bensalah4, Steven E Canfield5, Saeed Dabestani6, Rachel Giles7, Fabian Hofmann8, Milan Hora9, Markus A Kuczyk10, Thomas Lam11, Lorenzo Marconi12, Axel S Merseburger13, Alessandro Volpe14, Axel Bex15.   

Abstract

The European Association of Urology renal cancer guidelines have been updated to recommend nivolumab and cabozantinib over the previous standard of care in patients who have failed one or more lines of VEGF targeted therapy.
Copyright © 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26508312     DOI： 10.1016/j.eururo.2015.10.017

Source DB:  PubMed          Journal:  Eur Urol        ISSN： 0302-2838            Impact factor:   20.096


  29 in total

1.  Cabozantinib Versus Sunitinib As Initial Targeted Therapy for Patients With Metastatic Renal Cell Carcinoma of Poor or Intermediate Risk: The Alliance A031203 CABOSUN Trial.

Authors:  Toni K Choueiri; Susan Halabi; Ben L Sanford; Olwen Hahn; M Dror Michaelson; Meghara K Walsh; Darren R Feldman; Thomas Olencki; Joel Picus; Eric J Small; Shaker Dakhil; Daniel J George; Michael J Morris
Journal:  J Clin Oncol       Date:  2016-11-14       Impact factor: 44.544

2.  Clinical outcomes of the sequential use of pazopanib followed by everolimus for the treatment of metastatic renal cell carcinoma: A multicentre study in Korea.

Authors:  Jeong Ho Kim; Wan Lee; Tae Nam Kim; Jong Kil Nam; Tae Hyo Kim; Ki Soo Lee
Journal:  Can Urol Assoc J       Date:  2017-12-01       Impact factor: 1.862

Review 3.  Nivolumab in renal cell carcinoma: latest evidence and clinical potential.

Authors:  Camille Mazza; Bernard Escudier; Laurence Albiges
Journal:  Ther Adv Med Oncol       Date:  2016-12-11       Impact factor: 8.168

4.  International cancer seminars: a focus on kidney cancer.

Authors:  G Scelo; J N Hofmann; R E Banks; P Bigot; R S Bhatt; G Cancel-Tassin; S K Chew; C J Creighton; O Cussenot; I J Davis; B Escudier; T M Frayling; C Häggström; M A T Hildebrandt; I Holcatova; M Johansson; W M Linehan; D F McDermott; K L Nathanson; S Ogawa; E J Perlman; M P Purdue; P Stattin; C Swanton; N S Vasudev; X Wu; A Znaor; P Brennan; S J Chanock
Journal:  Ann Oncol       Date:  2016-04-29       Impact factor: 32.976

5.  Long noncoding RNA-SRLR elicits intrinsic sorafenib resistance via evoking IL-6/STAT3 axis in renal cell carcinoma.

Authors:  Z Xu; F Yang; D Wei; B Liu; C Chen; Y Bao; Z Wu; D Wu; H Tan; J Li; J Wang; J Liu; S Sun; L Qu; L Wang
Journal:  Oncogene       Date:  2016-11-14       Impact factor: 9.867

6.  Polypyrimidine Tract-Binding Protein 1 promotes proliferation, migration and invasion in clear-cell renal cell carcinoma by regulating alternative splicing of PKM.

Authors:  Junyi Jiang; Xu Chen; Hao Liu; Jing Shao; Ruihui Xie; Peng Gu; Chaohui Duan
Journal:  Am J Cancer Res       Date:  2017-02-01       Impact factor: 6.166

Review 7.  Current Clinical Practice Guidelines for the Treatment of Renal Cell Carcinoma: A Systematic Review and Critical Evaluation.

Authors:  Aristotle Bamias; Bernard Escudier; Cora N Sternberg; Flora Zagouri; Athanasios Dellis; Bob Djavan; Kimon Tzannis; Loukas Kontovinis; Konstantinos Stravodimos; Athanasios Papatsoris; Dionysios Mitropoulos; Charalampos Deliveliotis; Meletios-Athanasios Dimopoulos; Constantine A Constantinides
Journal:  Oncologist       Date:  2017-06-07

8.  Estrogen receptor β promotes renal cell carcinoma progression via regulating LncRNA HOTAIR-miR-138/200c/204/217 associated CeRNA network.

Authors:  Jie Ding; Chiuan-Ren Yeh; Yin Sun; Changyi Lin; Joshua Chou; Zhenyu Ou; Chawnshang Chang; Jun Qi; Shuyuan Yeh
Journal:  Oncogene       Date:  2018-05-23       Impact factor: 9.867

9.  Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma.

Authors:  Robert J Motzer; Bernard Escudier; Andrew Gannon; Robert A Figlin
Journal:  Oncologist       Date:  2016-11-02

10.  High fidelity of driver chromosomal alterations among primary and metastatic renal cell carcinomas: implications for tumor clonal evolution and treatment.

Authors:  Eril J Kouba; John N Eble; Novae Simper; David J Grignon; Mingsheng Wang; Shaobo Zhang; Lisha Wang; Guido Martignoni; Sean R Williamson; Matteo Brunelli; Claudio Luchini; Anna Calió; Liang Cheng
Journal:  Mod Pathol       Date:  2016-07-29       Impact factor: 7.842
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.